Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
296.76
-0.74 (-0.25%)
Jul 28, 2026, 2:55 PM EDT - Market open
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Ligand Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $323.3. The average 1-year stock price forecast is 8.94% higher than the current stock price, while the lowest is $247 (-16.77%) and the highest is $388 (+30.75%).
Price Target: $323.3 (+8.94%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 7 | 7 | 7 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Maintains $388 | Buy | Maintains | $388 | +30.75% | Jul 22, 2026 |
| Citi | Citi | Buy Initiates $387 | Buy | Initiates | $387 | +30.41% | Jul 21, 2026 |
| Benchmark Co. | Benchmark Co. | Buy Maintains $275 → $335 | Buy | Maintains | $275 → $335 | +12.89% | Jul 16, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $262 → $340 | Buy | Maintains | $262 → $340 | +14.57% | Jul 15, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jul 14, 2026 |
Financial Forecast
Revenue This Year
289.77M
from 268.09M
Increased by 8.09%
Revenue Next Year
375.37M
from 289.77M
Increased by 29.54%
EPS This Year
9.18
from 8.13
Increased by 12.97%
EPS Next Year
11.83
from 9.18
Increased by 28.80%
EPS and Forward PE are based on non-GAAP adjusted numbers.